Biora Therapeutics announced achievement of its device performance targets for the company’s BioJet platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine. The company announced during its recent quarterly conference call that it had preliminary results from animal testing indicating achievement of both its device function targets and its performance target of greater than or equal to 15% average bioavailability with the autonomous version of its next-generation device. As planned, the company subsequently conducted repeat studies and has now confirmed the achievement of its development targets for the BioJet platform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BIOR:
- Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
- Biora announces new patents covering its BioJet Systemic oral delivery platform
- Biora announces clinical device performance study results for NaviCap
- Biora Therapeutics to Report Second Quarter 2023 Financial Results and Provide Corporate Update